RT Journal Article
SR Electronic
T1 Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.03.21251054
DO 10.1101/2021.02.03.21251054
A1 Collier, Dami A.
A1 Ferreira, Isabella A.T.M.
A1 Kotagiri, Prasanti
A1 Datir, Rawlings
A1 Lim, Eleanor
A1 Touzier, Emma
A1 Meng, Bo
A1 Abdullahi, Adam
A1 ,
A1 Elmer, Anne
A1 Kingston, Nathalie
A1 Graves, Barbara
A1 Gresley, Emma Le
A1 Caputo, Daniela
A1 Smith, Kenneth GC
A1 Bradley, John R.
A1 Ceron-Gutierrez, Lourdes
A1 Cortes-Acevedo, Paulina
A1 Barcenas-Morales, Gabriela
A1 Linterman, Michelle
A1 McCoy, Laura
A1 Davis, Chris
A1 Thomson, Emma
A1 Lyons, Paul A.
A1 McKinney, Eoin
A1 Doffinger, Rainer
A1 Wills, Mark
A1 Gupta, Ravindra K.
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2021.02.03.21251054.abstract
AB Two dose mRNA vaccination provides excellent protection against SARS-CoV-2. However, there are few data on vaccine efficacy in elderly individuals above the age of 801. Additionally, new variants of concern (VOC) with reduced sensitivity to neutralising antibodies have raised fears for vulnerable groups. Here we assessed humoral and cellular immune responses following vaccination with mRNA vaccine BNT162b22 in elderly participants prospectively recruited from the community and younger health care workers. Median age was 72 years and 51% were females amongst 140 participants. Neutralising antibody responses after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old. Sera from participants below and above 80 showed significantly lower neutralisation potency against B.1.1.7, B.1.351 and P.1. variants of concern as compared to wild type. Those over 80 were more likely to lack any neutralisation against VOC compared to younger participants following first dose. The adjusted odds ratio for inadequate neutralisation activity against the B.1.1.7, P.1 and B.1.351 variant in the older versus younger age group was 4.3 (95% CI 2.0-9.3, p<0.001), 6.7 (95% CI 1.7-26.3, p=0.008) and 1.7 (95% CI 0.5-5.7, p=0.41). Binding IgG and IgA antibodies were lower in the elderly, as was the frequency of SARS-CoV-2 Spike specific B-memory cells. We observed a trend towards lower somatic hypermutation in participants with suboptimal neutralisation, and elderly participants demonstrated clear reduction in class switched somatic hypermutation, driven by the IgA1/2 isotype. SARS-CoV-2 Spike specific T-cell IFNγ and IL-2 responses fell with increasing age, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high risk population that warrant specific measures in order to mitigate against vaccine failure, particularly where variants of concern are circulating.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIHR BioresourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee (17EE0025). PBMC from unexposed volunteers previously recruited by the NIHR BioResource Centre Cambridge through the ARIA study (2014-2016), with ethical approval from the Cambridge Human Biology Research Ethics Committee (HBREC.2014.07) and currently North of Scotland Research Ethics Committee 1 (NS/17/0110).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from the corresponding author